Member Info for Bella6532

Wow that's a lot of Dox being pumped in...regardless of dosage, this is being pumped into people who have no other options...if this is reversing the tumour growth and extending their lives then that will be the best bloomin' news from this trial...not just the safety/dosage info.

Craiga24...you should be watching China...it hasn't and isn't going away. This winter is going to be very tricky...Covid will be back and so will flu...there will be a market for a duo very accurate test in places thst matter.

Moon shot...early Sept
Avacta...AVA6000 late Sept with or around results...other news I'm sure will drop sooner...

This is from Avacta Prelim 2020 Report:
'Pre|CISION can be widely applied to a range of other chemotherapies in a market
worth $56.5B with CAGR of 11.50% driven by increased cancer detection rates
Example: Velcade
• Bortezomib (Velcade, Takeda Pharmaceuticals) had
annual sales of $1.2bn (2018)
• BUT – approval limited to multiple myeloma
because of dose limiting toxicities,
• AND - coming off patent by 2022. '

So who is message sending to who...and who is targetting who...

137.2

It looks like it was held back to favour a work through. Now that's been completed the ropes are off.

MB53...next RNS will probably be Notice of Results...it would be nice to get something else prior to Results. End Sept should be a good time to update the markets re AVA6000 trial which is end Q3. Even if we don't get full blown data details, surely they can give an indication of how it's doing, next DE (if there is to be one) and a more accurate timeframe for data results etc...

There's lots more we could do with up dates on but I suspect the trial is where most investors focus lies.

And 'poof' no more unknowns and no more lates...just a little lonely UT...

From Deepverge BB...comment made by their CEO.
'Wich includes both the PD for water contamination and BT for the multiplex biomarker detection, of which SARS-CoV-2 is but one target pathogen. This is a digital health medical device and rolling it out for a single biomarker is not viable when it is to be used in a clinical diagnostic laboratory or eventually small enough to be used in an GP office.

That is nearly 10 times what was spent in R&D in 2020 Some of that is on BT. Progress is being made and while it may not be detecting COVID in test centers we are falling behind on delivery taking into account the time it takes to bring a medical device to market.'

Avacta and Deepverge still working together. Interesting statement made by Deepverge may be a bit of a clue as to what Avacta might be looking at too.

thevid...thank you

Thank you Gerry.
Regarding the BT, based on recent RNSs etc have you completely moved away from using any Avacta affimers?

Thanks Ophidian...couldn't have put it better myself.
I assume much of the data procured will be looking for how much of the AVA6000 make up (Dox/5140 etc) remains in the tumour(s) vs how much of ehat migrates out...if this is the case then surely by default they will be able to determine AVA6000 efficacy since it's a simple case of it's inert/harmless or not. In the case of 'not' that's where I assume the next trials come into play.

Let's see if this one gets taken down too...
Recent Share Trades for Avacta (AVCT)
Date Time Trade Prc Volume Buy/Sell Value
05-Aug-22 17:23:18 111.00 8,960 Unknown* 9,946 O
04-Aug-22 10:18:24 115.00 25,000 Unknown* 28.75k O
04-Aug-22 09:47:20 115.50 25,000 Unknown* 28.88k O
04-Aug-22 10:17:36 115.00 25,000 Unknown* 28.75k O
04-Aug-22 09:41:35 115.50 25,000 Unknown* 28.88k O
04-Aug-22 13:43:04 115.00 25,000 Unknown* 28.75k O
04-Aug-22 08:47:06 116.50 25,000 Unknown* 29.13k O
05-Aug-22 17:08:07 111.00 200 Unknown* 222.00 O
05-Aug-22 16:35:21 111.00 4,140 Unknown* 4,595 UT

I see my post with last nights late trades was removed...haha...they don't want you to see them and the insults are flying...all tells you an order is being worked..

BB...finger in the air guess...
Total Rev £426K (as stated by PXS
made up as follows:
AA £278K
PXS including H&B/Amazon £68K
Distributor £80K

The Distributor pays up front so agree income and shipping could be in different years. Same could apply for any year if there is a long lead time from the manufacturer.

Sells made to look like Buys by dropping the Bid...mmmm!
My guess is we will see more unknows or even Buys after hours again today.
Order filling being worked!!?

This is my breakdown - corrected:
2020/2021 FY Total Income £505K
made up as follows:
AA £358K

FF+O Direct Sales (Net of Rebates) £138K including H&B/Amazon
(PXS H1 = £30K H2 = £31K Total = £61K)
(Distributor H1 = £27K H2 = £50K Total for the year = £77K)

FF+N 9K (development income)

Now there's an added question...if the Distributor sales did not go through the J&J O/N system and shipped direct then the price per unit/order would be even worse again.

Anyone else got any bright ideas on all this???

This is my breakdown:
2020/2021 FY Total Income £505K
made up as follows:
AA £358K
FF+O Direct Sales (Net of Rebates) £138K including H&B/Amazon
FF+N 9K (development income)
Distributor H1 = £27,000 H2 = £50,000 Total for the year = £77K

Now for H1 2021/22 Total Income = £211K
AA £135,188
Direct £76,007 (I estimate PXS Sales = £36,007 and Distributor = £40,000)

For H2 2021/22
I estimate PXS Sales to be in the region of £32 - £33K
Obviously can't go further with other amounts until the Y/E Results are issued.

Before anyone asks...the above are either based on my own personal estimates and numbers officially put out by the company in their results.